Awareness of pathophysiological concepts of type 2 diabetes-A survey in 847 physicians

Diabetes Research and Clinical Practice

Volumn 76, Issue 3, 2007, Pages 445-448

  Busse, Franziska P ^a   Denti, Veronica ^b   Stumvoll, Michael ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Beta cell dysfunction; GLP 1; Glucacon; Incretins; Insulin resistance

Indexed keywords

GLUCAGON;

ARTICLE; AWARENESS; CLINICAL PRACTICE; FRANCE; GERMANY; HEALTH SURVEY; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; ONLINE ANALYSIS; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; PHYSICIAN; PRIMARY MEDICAL CARE; UNITED KINGDOM; UNITED STATES;

CLINICAL COMPETENCE; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-SECRETING CELLS; GLUCOSE; HUMANS; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; LIVER; ONLINE SYSTEMS; PRIMARY HEALTH CARE; QUESTIONNAIRES;

EID: 33947604097     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2006.09.037     Document Type: Article

References (26)

1. Pratley R.E., and Weyer C. The role of impaired insulin secretion in the pathogenesis of type 2 diabetes mellitus. Diabetologia 44 (2001) 929-945
2. Errikson J., Franssila-Kallunki A., Ekstrand A., et al. Early metabolic effects in persons at increased risk for non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 321 (1998) 337-343
3. Dinneen M., Gerich J., and Rizza R. Carbohydrate metabolism in non-insulin-dependent diabetes mellitus. N. Engl. J. Med. 104 (1992) 787-794
4. Wallace T.M., and Matthews D.R. The assessment of insulin resistance in man. Diab. Med. 19 (2002) 527-534
5. Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 48 (1999) 2197-2203
6. Rajala W.M., and Scherer P.E. Minireview: the adipocyte- at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology 144 (2003) 3765-3773
7. Ravussin E., and Smith S.R. Increased fat intake, impaired fat oxidation, and failure of fat cell proliferation result in ectopic fat storage, insulin resistance and type 2 diabetes mellitus. Ann. N. Y. Acad. Sci. 976 (2002) 363-378
8. Hotamisligil G.S. Molecular mechanisms of insulin resistance and the role of the adiopocyte. Int. J. Obese. Relat. Metab. Disord. 24 Suppl. 4 (2000) S23-S27
9. Kelley D.E., Menshikova J., and Ritov V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51 (2002) 2944-2950
10. Weyer C., Bogardus C., Mott D.M., and Pratley R.E. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes. J. Clin. Invest. 104 (1999) 787-794
11. van Haeften T.W., Pimenta W., Mitrakou A., et al. Disturbances in beta-cell function in impaired fasting glycemia. Diabetes 51 Suppl. 1 (2002) 265-270
12. Kaneto H., Kawamori D., Matsuoka T.A., Kajimoto Y., and Yamasaki Y. Oxidative stress and pancreatic beta-cell dysfunction. Am. J. Ther. 12 (2005) 529-533
13. Yki Jaervinen H. Glucose toxicity. Endocr. Rev. 13 (1992) 415-431
14. Janson J., Ashley R.H., Harrison D., McIntyre S., and Butler B.J. The mechanisms of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48 (1999) 491-498
15. Stumvoll M., Goldstein B.J., and van Haeften T.W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 356 (2005) 1333-1346
16. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346 (2002) 393-403
17. Buchanan T. Pancreatic beta cell loss and preservation in type 2 diabetes. Clin. Ther. 23 Suppl. B (2003) B32-B46
18. Drucker D.J. The biology of incretin hormones. Cell Metab. 3 3 (2006) 153-165
19. Mest H.J. Dipedtidy peptidase-IV inhibitors can restore glucose homeostasis in type 2 diabetics via incretin enhancement. Curr. Opin. Invest. Drugs 7 4 (2006) 338-343
20. Gallwitz B. Therapies for the treatment of type 2 diabetes mellitus based on incretin action. Minerva Endocrinol. 31 2 (2006) 133-147
21. Holst J.J. Glucagon-like pepide-1: from extract to agent. The Claud Bernard Lecture. Diabetologia 49 2 (2006) 253-260
22. Chiasson J.L., Brindisi M.C., and Rabasa-Lhoret R. The prevention of type 2 diabetes: what is the evidence?. Minerva Endocrinol. 30 3 (2005) 179-191
23. Lebowitz H.E. Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. Endocr. Prac. 12 Suppl. 1 (2006) 142-147
24. Stumvoll M., Häring H., and Fritsche A. For debate: Starling's curve of the pancreas- overuse of a concept?. Horm. Metab. Res. 35 (2003) 391-395
25. Gautier J.F., Wilson C., Weyer C., Mott D., Knowler W.C., Cavaghan M., et al. Low acute insulin secretory responses in adult offspring of people with early onset type 2 diabetes. Diabetes 50 8 (2001) 1828-1833
26. Kruger D.F., Martin C.L., and Sadler C.E. New insights into glucose regulation. Diab. Educ. 32 2 (2006) 221-228